FX-322 in Adults With Stable Sensorineural Hearing Loss

Sensorineural Hearing Loss Clinical Trial

Official title:

A Phase 2a, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single and Repeat-Dose, Multicenter, Exploratory Efficacy Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04120116
• Other study ID #: FX-322-202
• Status: Completed
• Phase: Phase 2
• Start date: October 4, 2019
• Est. completion date: December 17, 2020

Study information

• Verified date: April 2023
• Source: Frequency Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2a single and repeat dose exploratory efficacy study of intratympanic FX-322 compared to placebo in healthy male and female adults with stable sensorineural hearing loss.

Description:

Sensorineural hearing loss (SNHL) accounts for about 90% of all cases of hearing loss. This phase 2a study will assess the exploratory efficacy, as well as the local and systemic safety of single and repeat intratympanic doses of FX-322 compared to placebo in approximately 96 subjects with stable mild to moderately severe sensorineural hearing loss, with a medical history consistent with either excessive noise exposure or idiopathic sudden sensorineural hearing loss.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 95
• Est. completion date: December 17, 2020
• Est. primary completion date: October 6, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Adults aged 18-65 years inclusive.

2. Established diagnosis of stable sensorineural hearing loss by standard audiometric measures for = 6 months prior to the Screening visit (no changes in air conduction greater than 10 dB at a single frequency or greater than 5 dB at two contiguous frequencies from the prior audiogram to the Screening audiogram in the study ear).

3. Documented medical history consistent with hearing loss being caused by noise exposure or sudden sensorineural hearing loss.

4. Pure Tone Audiometry (PTA) within 26-70 dB in the ear to be injected.

5. Female subjects must be of non-childbearing potential or will need to utilize two methods of highly effective contraception during the study participation (e.g. hormonal contraception or an intrauterine device and condoms) or remain abstinent. Male subjects should use condoms with spermicide during the course of the study or remain abstinent. Subjects should not donate sperm or ova during the study period.

Exclusion Criteria:

1. Previous participation in FX-322 clinical trial.

2. Currently on any medication consisting of valproic acid, valproate sodium, or divalproex sodium.

3. Perforation of tympanic membrane or other tympanic membrane disorders that would interfere with the delivery and safety assessment of an intratympanic medication or reasonably be suspected to affect tympanic membrane healing after injection in study ear. This includes a current tympanostomy tube.

4. Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10 dB at two or more contiguous octave frequencies in the study ear at the Screening visit or on the prior audiogram (if the Investigator feels there is not a true conductive hearing loss, the Medical Monitor should be consulted).

5. Active chronic middle ear disease or a history of major middle ear surgery, as an adult, in the ear to be injected.

6. Subject has had an intratympanic injection in either ear within 6 months of the screening visit.

7. History of clinically significant vestibular symptoms at the discretion of the investigator.

8. History of clinically significant systemic autoimmune disease.

9. History of head or neck radiation treatment or exposure.

10. History of platinum-based chemotherapy treatment.

11. Exposure to another investigational drug within 28 days prior to injection of study drug.

12. Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator following a detailed medical history, physical examination, and vital signs (systolic and diastolic blood pressure, pulse rate, body temperature).

13. History of substance abuse within 2 years of the Screening Visit.

14. Positive test for drugs of abuse at screening.

15. Positive urine pregnancy test or breast-feeding.

16. Any known factor, condition or disease that, in the view of the Investigator, might interfere with treatment compliance, study conduct or interpretation of the results (e.g. previous high-dose aminoglycoside treatment).

Related Conditions & MeSH terms

• Deafness
• Hearing Loss
• Hearing Loss, Noise-Induced
• Hearing Loss, Sensorineural
• Noise Induced Hearing Loss
• Sensorineural Hearing Loss
• Sudden Sensorineural Hearing Loss

Intervention

Drug:
• FX-322 (One Dose)
Patients will receive one dose of FX-322.
• FX-322 (Two Doses)
Patients will receive two doses of FX-322.
• FX-322 (Four Doses)
Patients will receive four doses of FX-322.
• Placebo
Patients will receive Placebo.

Locations

Country	Name	City	State
United States	Clinical Trial Site	Amherst	New York
United States	Clinical Trial Site	Austin	Texas
United States	Clinical Trial Site	Boca Raton	Florida
United States	Clinical Trial Site	Colorado Springs	Colorado
United States	Clinical Trial Site	Fresno	California
United States	Clinical Trial Site	Louisville	Kentucky
United States	Clinical Trial Site	Matthews	North Carolina
United States	Clinical Trial Site	Omaha	Nebraska
United States	Clinical Trial Site	Orangeburg	South Carolina
United States	Clinical Trial Site	Richmond	Virginia
United States	Clinical Trial Site	San Antonio	Texas
United States	Clinical Trial Site	San Antonio	Texas
United States	Clinical Trial Site	Sarasota	Florida
United States	Clinical Trial Site	Tampa	Florida
United States	Clinical Trial Site	Torrance	California
United States	Clinical Trial Site	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Frequency Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Word Recognition in Quiet	Percent of subjects exceeding the Carney-Schlauch 95% confidence interval for improvement from baseline in number of words recognized from Consonant-Nucleus-Consonant (CNC) word lists	Baseline to Day 210
Primary	Words-in-Noise	Mean absolute percent change in number of recognized words from CNC word lists	Baseline to Day 210
Primary	Pure Tone Audiometry	Mean overall pure tone average (PTA) hearing thresholds in decibels (dB) derived by averaging the air conduction thresholds at 0.5, 1, 2 and 4kHZ frequencies	Baseline to Day 210
Primary	Treatment-emergent Adverse Events (TEAEs)	Number of patients with treatment-related adverse events assessed by CTCAE v5.0	Baseline to Day 210
Primary	Otoscopy Abnormalities	Number of treated ears with abnormalities of the external ear canal, tympanic membrane and middle ear at each specified time point	Baseline and Days 8, 15, 21 60, 90,150, and 210
Primary	Tympanometry Abnormalities	Number of treated ears with changes in middle ear compliance (mL), peak pressure (daPa), and/or ear canal volume (mL) from baseline	Baseline and Days 15, 60, 90, 150, 210